Company / Revenue per Share
CRISPR Therapeutics AG Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.04
FY2025
5-year range
$0.02 / $11.88
FY2021-FY2025
Trend
-91.6%
vs FY2024
Sector context
#143 of 154
Health Care
What the data says
Among 154 Health Care companies, CRISPR Therapeutics AG is in the bottom 7% for revenue per share. Revenue per Share has fluctuated over the past 10 years, ranging from $0.01 in FY2017 to $11.88 in FY2021.
Based on SEC 10-K filings.
0.04 in FY2025 with a 5-year CAGR of +30.3%.
Declined from $4.64 to $0.04 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +33.9%
- 5-Year CAGR
- +30.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 154This company $0.04 Sector average $14.98
▼
-99.8% below sector average
Key checks
Key Insights
- In FY2025, revenue per share decreased 91.6% year-over-year.
- Ranks #143 out of 154 companies in the Health Care sector.
- Peak revenue per share was recorded in FY2021.
- Lowest revenue per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.04 | -91.6% |
| FY2024 | $0.44 | -90.6% |
| FY2023 | $4.64 | +30292.5% |
| FY2022 | $0.02 | -99.9% |
| FY2021 | $11.88 | +122072.0% |
| FY2020 | $0.01 | +53.8% |
| FY2019 | $0.01 | -95.0% |
| FY2018 | $0.13 | +1945.7% |
| FY2017 | $0.01 | -86.1% |
| FY2016 | $0.04 | -8.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026